A targeted immunotherapy approach for HER2/neu transformed tumors by coupling an engineered effector domain with interferon-Î³.

Zhang, Hongtao; Lam, Lian; Nagai, Yasuhiro; Zhu, Zhiqiang; Chen, Xi; Ji, Mei Q; Greene, Mark I

Zhang, Hongtao; Lam, Lian; Nagai, Yasuhiro; Zhu, Zhiqiang; Chen, Xi; Ji, Mei Q; Greene, Mark I.

Afiliación

Zhang H; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Lam L; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Nagai Y; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Zhu Z; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Chen X; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Ji MQ; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Greene MI; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Oncoimmunology ; 7(4): e1300739, 2018.

Article en En | MEDLINE | ID: mdl-29632709

Palabras clave

Antibody; HER2; IFNÎ³; cancer; engineered effector domain (EED)

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Oncoimmunology Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google